News

Mr Shanahan is the former president of Colgate-Palmolive Company and currently serves on the board of directors of Visa, Diageo and MSD Ignition, a privately held company. Mr

With the completion of this pivotal phase, Musculoskeletal Transplant Foundation (MTF) has successfully delivered to Orthofix a conclusive data package meeting the specifications provided by Orthofix under the

According to the company, the ViaDerm system provides a self-administered solution that enables the safe, reproducible and accurate delivery of a broad range of product candidates, including hydrophilic

Under the terms of the agreement, Teva will finance Jexys’s R&D program for the development of a high throughput drug discovery platform and in return will receive a

The products include Proteoderm’s special high end formulation and an over-the-counter formulation, currently under development. Proteoderm intends to sell to Sinoquest the pre-mixed material in bulk and a

Ortho-McNeil’s Phase I program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil’s planned clinical studies

The study is an open-label, dose-escalation trial expected to enroll up to 18 patients and to test three dose levels of FG-3019 administered via infusion every two weeks.

The Cross-Pilot is a laser support catheter for the 0.9 Turbo Elite laser ablation catheter. The Cross-Pilot was designed to provide additional support for reaching distal lesions. The

The trial is planned to be a 28-day multi-center, randomized, double-blind, placebo controlled study to assess the efficacy of topical SYI-2074, applied twice daily, for the treatment of